Is Aduro Biotech (ADRO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/28/20
Aduro Biotech (ADRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/19/20
Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung CancerGlobeNewsWire • 02/06/20
Aduro Biotech (ADRO) Up 7.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/07/19
Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual MeetiGlobeNewsWire • 11/08/19
Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)GlobeNewsWire • 10/02/19
Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)GlobeNewsWire • 09/04/19
Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment ConferenceGlobeNewsWire • 09/03/19
Why Is Aduro Biotech (ADRO) Down 12.1% Since Last Earnings Report?Zacks Investment Research • 08/31/19
Why Is Aduro Biotech (ADRO) Down 10.7% Since Last Earnings Report?Zacks Investment Research • 03/29/19